References
- 1. Cataldo MA et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections, systematic review and meta-analysis. // J Antimicrob Chemother, 2012; 67(1):17-24.
- 2. Devabhakthuni S. Antibiotic Pharmacokinetic Monitoring. // Published 2011. Retrieved on May 22, 2013 from www.ashp.org/DocLibrary/MemberCenter/NPF/2011Pearls/Antibiotic-Pharmacokinetic-Monitoring.aspx
- 3. Di Filippo A et al. Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. // Chemotherapy, 1998; 44(1):63-68.
- 4. Hidayat LK et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections, efficacy and toxicity. // Arch Intern Med, 2006; 166:2138-2144.
- 5. Ibrahim NS et al. Time to Achieving Target Concentration of Vancomycin, Intermittent Infusion versus Continuous Infusion of Vancomycin in Intensive Care Unit. // Published 2011. Retrieved on March 22, 2013 from http://www.kck.usm.my/husm/pharmacy/images/penerbitan
- 6. Jeffres MN et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with healthcare-associated methicillinresistant Staphylococcus aureus pneumonia. // Clin Ther, 2007; 29:1107-1115.
- 7. Law Min C, Bourne R. Continuous Vancomycin Infusion Guidelines in Critical Care. // Sheffield Teaching Hospitals NHS Foundation Trust Guidelines, 2012.
- 8. Lodise TP et al. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. // Antimicrob Agents Chemotherapy, 2008; 52:1330-1336.
- 9. Nguyen M et al. Nephrotoxicity associated with high dose vs standard dose vancomycin therapy. // In: 47th Interscience Conference on Antimicrob Agents Chemotherapy. 2007; Chicago, IL, September 2007.
- 10. Pauly DJ et al. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. // Pharmacotherapy, 1990; 10:378-382.
- 11. Pea F et al. Prospectively validated dosing nomograms for maximizing pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. // Antimicrob Agents Chemotherapy, 2009; 53(5):1863-1867.
- 12. Rello J et al. Pneumonia caused by oxacillinresistant Staphylococcus aureus treated with glycopeptides. // Crit Care Med, 2005; 33(9):1983-1987.
- 13. Roberts JA et al. Better outcomes through continuous infusion of time dependent antibiotics to critically ill patients? // Curr Opin Crit Care, 2008; 14:390-396.
- 14. Roberts JA, Lipman J. Antibacterial dosing in intensive care, pharmacokinetics, degree of disease and pharmacodynamics of sepsis. // Clin Pharmacokinet, 2006; 45:755-773.
- 15. Rybak MJ et al. Vancomycin Therapeutic Guidelines, A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. // Clin Infect Dis, 2009; 49:325-327.
- 16. Rybak MJ, Lomaestro B. Therapeutic monitoring of vancomycin in adult patients, A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. // AJHP, 2009; 66:82 - 98.
- 17. Rybak MJ et al. Nephrotoxicity of vancomycin alone and with an aminoglycoside. // J Antimicrob Chemother, 1990; 25:679-687.
- 18. Vuagnat A et al. High dose vancomycin for osteomyelitis, continuous vs intermittent infusion. // J Clin Pharm Ther, 2004; 29(4):351-357.
- 19. Wysocki M et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections, prospective multicenter randomized study. // Antimicrob Agents Chemotherapy, 2001; 45(9):2460-2467.